Original Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Jun 7, 2010; 16(21): 2638-2647
Published online Jun 7, 2010. doi: 10.3748/wjg.v16.i21.2638
Table 3 Patients’ baseline oxidative stress parameters and outcome at 6 mo
VariableViusid (n = 30)
Placebo (n = 30)
P value1
Before treatmentAfter treatmentChangeP valueBefore treatmentAfter treatmentChangeP value
MDA (μmol/L)0.97 ± 0.050.29 ± 0.05-0.68 ± 0.08< 0.0011.12 ± 0.090.76 ± 0.08-0.36 ± 0.120.0020.001
4-hydroxyalkenals (μmol/L)1.75 ± 0.090.53 ± 0.06-1.22 ± 0.1< 0.0011.92 ± 0.141.39 ± 0.13-0.53 ± 0.20.010.001
Cu/Zn SOD (U/mg Hb)17.6 ± 1.13.26 ± 0.4-14.3 ± 1.2< 0.00118.7 ± 0.93.44 ± 0.39-15.3 ± 1.04< 0.0010.71
CAT (U/mg Hb)235 ± 23.717.6 ± 2.3-217.4 ± 24< 0.001289 ± 21.821 ± 2.7-268 ± 22< 0.0010.13
GR (mU/mg Hb)6.1 ± 0.711 ± 1.14.9 ± 1.3< 0.0016.9 ± 1.112 ± 1.25.1 ± 1.60.0010.97
GPx (mU/mg Hb)169 ± 11.6147 ± 12-22 ± 170.20176 ± 11.2136 ± 16-40 ± 190.050.87
GSH (μmol/L)26.3 ± 2.316.4 ± 1.9-9.9 ± 30.00231.8 ± 3.219.8 ± 2.5-12 ± 4.10.0050.69
MPO (ng/mL)221 ± 6.6123 ± 12.9-98 ± 14.2< 0.001221 ± 6.7115 ± 22-106 ± 23.2< 0.0010.61
AOPP (μmol/L)36.1 ± 5.448.4 ± 13.712.3 ± 11.20.3926.2 ± 5.535.9 ± 7.69.7 ± 9.30.300.57